Form 8-K - Current report:
SEC Accession No. 0000950170-21-003301
Filing Date
2021-11-08
Accepted
2021-11-08 07:07:54
Documents
14
Period of Report
2021-11-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20211108.htm   iXBRL 8-K 51844
2 EX-99.1 axsm-ex99_1.htm EX-99.1 152032
3 GRAPHIC img36028404_0.jpg GRAPHIC 55046
  Complete submission text file 0000950170-21-003301.txt   406462

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axsm-20211108.xsd EX-101.SCH 2469
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axsm-20211108_pre.xml EX-101.PRE 9441
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axsm-20211108_lab.xml EX-101.LAB 12798
7 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20211108_htm.xml XML 4540
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 211386500
SIC: 2834 Pharmaceutical Preparations